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Table 2.1: Data collected at baseline and 12-month follow-up appointments 
Variable Baseline 12-month follow-up 
Age YES NO 
Gender YES NO 
Ethnicity YES YES 
BMI YES YES 
Smoking status YES YES 
Macrovascular complications YES YES 
PHQ-9 YES YES 
HbA1c YES YES 
Lipids YES YES 
CRP YES YES 
IL-4 YES NO 
IL-6 YES NO 
IL-10 YES NO 
VEGF YES NO 
TNF-α YES NO 
IL-1β YES NO 
IL-1RA YES NO 
MCP-1 YES NO 
WBC YES NO 
TGL YES YES 
Adiponectin YES NO 
Medications with anti-inflammatory action YES YES 





















































































































































































































































































































































































































































































































































































































































































































Table 3.1: Baseline characteristics of participants with type 2 diabetes mellitus in the South 
London Diabetes Study stratified by whether there was a frozen serum sample for cytokine 
array for subjects 
Baseline variable Total 
(n = 1769) 
Serum Sample 
(n = 1227) 
No Serum 
Sample 
(n = 542) 
p-value 
Mean age, years 56.1 (11.04) 56.7 (10.99) 54.8 (11.01) 0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 675 (55.0) 301 (55.5) 0.838 
793 (44.8) 552 (45.0) 241 (44.5) 
     




878 (49.6) 660 (53.8) 218 (40.2) <0.001* 
710 (40.1) 439 (35.8) 271 (50.0) 
181 (10.2) 128 (10.4) 53 (9.8) 
     
HbA1c     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Psychological assessment     
Median PHQ-9 score 3.0 (0.0-6.0) 2.0 (0.0-7.0) 3.0 (0.0-6.0) 0.042* 
PHQ-9 depression (%) 258 (14.6) 167 (13.6) 91 (16.8) 0.081 
*significant α=0.05. T-test and Mann Witney U test used for normal and non-normal data 
Table 3.2: Baseline characteristics of participants with type 2 diabetes mellitus in the South 
London Diabetes Study stratified by whether there was a serum sample (for CRP analysis) 
for subjects 
Baseline variable Total 
(n = 1769) 
Serum Sample 
(n = 1461) 
No Serum 
Sample 
(n = 308) 
p-value 
Mean age, years 56.1 (11.04) 56.4 (10.86) 54.5 (11.72) 0.006* 
     
Gender (%)     
Male 
Female 
976 (55.2) 797 (54.6) 179 (58.1) 0.253 
793 (44.8) 664 (45.4) 129 (41.9) 
     




878 (49.6) 738 (50.5) 140 (45.5) 0.144 
710 (40.1) 571 (39.1) 139 (45.1) 
181 (10.2) 152 (10.4) 29 (9.4) 
     
HbA1c     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Psychological assessment     
Median PHQ-9 score 3.0 (0.0-6.0) 3.0 (0.0-6.0) 2.6 (0.0-6.0) 0.789 
PHQ-9 depression (%) 258 (14.6) 212 (14.5) 46 (14.9) 0.848 
*significant α=0.05. T-test and Mann Whitney U test used for normal and non-normal data 
 88 
Table 3.3a: Baseline characteristics of depression cases (PHQ-9 ≥ 10) and non-depressed (PHQ-9 < 10) 
subjects with type 2 diabetes mellitus in the South London Diabetes Study 
Baseline variable Total 
(n = 1769) 
No depression  
(n = 1511) 
Depression 
(n = 258) 
p-value 
Mean age, years 56.1 (11.04) 56.6 (11.05)  53.0 (10.40) <0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 855 (56.6) 121 (46.9) 0.004* 
793 (44.8) 656 (43.4) 137 (53.1) 
     




878 (49.6) 750 (49.6) 128 (49.6) 0.128 
710 (40.1) 615 (40.7) 95 (36.8) 
181 (10.2) 146 (9.7) 35 (13.6) 
     
Mean % HbA1c 
(Mean HbA1c, mmol/mol) 







     
Lipids     
Median triglyceride,  
mmol/L 
1.40 (0.90-2.00) 1.40 (0.90-1.90) 1.50 (1.00-2.20) 0.003† 
Mean low density 
lipoprotein, mmol/L 
2.6 (0.91) 2.63 (0.90) 2.65 (0.98) 0.792 
Mean high density 
lipoprotein, mmol/L 
1.2 (0.34) 1.22 (0.33) 1.20 (0.39) 0.589 
Mean total cholesterol, 
mmol/L 
4.6 (1.09) 4.56 (1.06) 4.69 (1.23) 0.097 
     
Mean body mass index, 
kg/m2 
32.0 (6.50) 31.8 (6.34) 33.4 (7.23) 0.001* 
     
Macrovascular disease (%)     
None 1584 (90.8) 1365 (91.5) 219 (86.2) 0.007* 
More than 1 161 (9.2) 126 (8.5) 35 (13.8) 
    
Smoking Status (%)     
Smoker 353 (21) 271 (18.8) 82 (34.3) <0.001* 
Non-Smoker 1324 (79) 1167 (81.2) 157 (65.7)  
     
Inflammatory markers     
Median CRP, mg/L  2.90 (1.20-6.40) 2.70 (1.10-6.20) 3.25 (1.40-8.70) 0.002† 
Median IL-4, ng/L 1.34 (1.11-1.68) 1.34 (1.10-1.68) 1.35 (1.17-1.68) 0.380 
Median IL-6, ng/L 1.35 (0.68-3.42) 1.32 (0.67-3.41) 1.40 (0.75-3.63)  0.420 
Median IL-10, ng/L 0.45 (0.34-0.63) 0.44 (0.34-0.63) 0.47 (0.35-0.68) 0.144 
Median VEGF ,ng/L 75.3 (44.8-119.3) 74.6 (44.9-118.2) 83.29 (44.9-128.7) 0.589 
Median TNF-α, ng/L 0.89 (0.39-1.86) 0.89 (0.39-1.88) 0.91 (0.43-1.76) 0.771 
Median IL-1β, ng/L 1.02 (0.73-1.87) 1.01 (0.72-1.85) 1.12 (0.76-2.06) 0.191 
Median IL-1RA, ng/L 437 (292.0-694.8) 430.0 (282.9-672.4) 488.8 (337.3-785.3) 0.003† 
Median MCP-1, ng/L 103.3 (60.2-152.9) 101.7 (59.3-151.1) 112.1 (62.8-162.6) 0.134 
Median WBC, x109/L 6.51 (5.31-7.97) 6.44 (5.25-7.86) 6.91 (5.74-8.56) <0.001† 
Median adiponectin, mg/L 4.94 (3.28-7.50) 5.01 (3.29-7.61) 4.65 (3.27-6.65) 0.097 
*significant α=0.05. 
†significant after Simes’ improved Bonferroni correction for multiple testing. 
Missing or incomplete values for: HbA1c = 117 cases, lipids = 245 cases, BMI = 3 cases, macrovascular 
history = 24 cases, smoking status = 92 cases, CRP = 308 cases, WBC = 183 cases, adiponectin = 304 cases. 
Values for IL-4, IL-6, IL-10, VEGF, TNF-α, IL-1β, IL-1RA, MCP-1 were for a subset of first 1227 subjects for 
































Table 3.3b: Baseline characteristics of depression cases (PHQ-9 ≥ 12) and non-depressed (PHQ-9 < 12) 
subjects with type 2 diabetes mellitus in the South London Diabetes Study 
Baseline variable Total 
(n = 1769) 
No depression  
(n = 1571) 
Depression 
(n = 198) 
p-value 
Mean age, years 56.1 (11.04) 56.5 (11.03)  52.6 (10.43) <0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 884 (56.3) 92 (46.5) 0.009* 
793 (44.8) 687 (43.7) 106 (53.5) 
     




878 (49.6) 783 (49.8) 95 (48.0) 0.050 
710 (40.1) 637 (40.5) 73 (36.9) 
181 (10.2) 151 (9.6) 30 (15.2) 
     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Lipids     
Median triglyceride,  
mmol/L 
1.40 (0.90-2.00) 1.40 (0.90-1.90) 1.40 (1.00-2.10) 0.053 
Mean low density 
lipoprotein, mmol/L 
2.63 (0.91) 2.63 (0.91) 2.63 (0.94) 0.961 
Mean high density 
lipoprotein, mmol/L 
1.22 (0.34) 1.22 (0.33) 1.18 (0.35) 0.126 
Mean total cholesterol, 
mmol/L 
4.57 (1.09) 4.58 (1.09) 4.58 (1.11) 0.937 
     
Mean body mass index, 
kg/m2 
32.0 (6.50) 31.8 (6.45) 33.6 (6.70) <0.001* 
     
Macrovascular disease (%)     
None 1584 (90.8) 1419 (91.5) 165 (84.6) 0.002* 
More than 1 161 (9.2) 131 (8.5) 30 (15.4) 
    
Smoking Status (%)     
Smoker 353 (21) 292 (19.6) 61 (32.4) <0.001* 
Non-Smoker 1324 (79) 1197 (80.4) 127 (67.6)  
     
Inflammatory markers     
Median CRP, mg/L  2.90 (1.20-6.40) 2.70 (1.10-6.18) 3.40 (1.55-9.35) <0.001† 
Median IL-4, ng/L 1.34 (1.11-1.68) 1.34 (1.10-1.68) 1.37 (1.21-1.70) 0.169 
Median IL-6, ng/L 1.35 (0.68-3.42) 1.32 (0.67-3.33) 1.48 (0.80-5.92)  0.133 
Median IL-10, ng/L 0.45 (0.34-0.63) 0.44 (0.34-0.63) 0.47 (0.34-0.68) 0.374 
Median VEGF ,ng/L 75.3 (44.8-119.3) 74.73 (44.8-118.4) 82.22 (45.4-129.6) 0.588 
Median TNF-α, ng/L 0.89 (0.39-1.86) 0.89 (0.39-1.87) 0.89 (0.43-1.79) 0.761 
Median IL-1β, ng/L 1.02 (0.73-1.87) 1.01 (0.73-1.84) 1.15 (0.77-2.55) 0.123 
Median IL-1RA, ng/L 437 (292.0-694.8) 429.1 (286.9-664.0) 529.3 (366.2-808.0) <0.001† 
Median MCP-1, ng/L 103.3 (60.2-152.9) 101.1 (59.2-151.1) 118.4 (66.3-166.6) 0.052 
Median WBC, x109/L 6.51 (5.31-7.97) 6.45 (5.26-7.88) 6.91 (5.82-8.53) <0.001† 
Median adiponectin, mg/L 4.94 (3.28-7.50) 4.99 (3.27-7.62) 4.71 (3.30-6.49) 0.134 
*significant α=0.05. 
†significant after Simes’ improved Bonferroni correction for multiple testing. 
Missing or incomplete values for: HbA1c = 117 cases, lipids = 245 cases, BMI = 3 cases, macrovascular 
history = 24 cases, smoking status = 92 cases, CRP = 308 cases, WBC = 183 cases, adiponectin = 304 cases. 
Values for IL-4, IL-6, IL-10, VEGF, TNF-α, IL-1β, IL-1RA, MCP-1 were for a subset of first 1227 subjects for 





Table 3.4: Unadjusted Spearman’s ranked correlations for association between inflammatory 
marker concentration and PHQ-9 score for the baseline SOULD cohort (n=1227). 
 
Inflammatory marker rs p-value 
CRP  0.15 <0.001* 
IL-4  0.06   0.056 
IL-6  0.05   0.075 
IL-10  0.05   0.105 
VEGF  0.07   0.012* 
TNF-α  0.02   0.404 
IL-1β  0.09   0.003* 
IL-1RA  0.16 <0.001* 
MCP-1  0.08   0.005* 
WBC  0.13 <0.001* 
TGL  0.11 <0.001* 
Adiponectin -0.07   0.010* 













Table 3.5: Unadjusted Spearman’s ranked correlations of inflammatory markers with each other, PHQ-9 score, BMI and HbA1c n = 1227 
 PHQ-9	 CRP	 IL-4	 IL-6	 IL-10	 VEGF	 TNF-α	 IL-1β	 IL-1RA	 MCP-1	 WBC	 TGL	 Adiponectin	 BMI	 HbA1c	
PHQ-9	
 
.153	 .055	 .051	 .046	 .072	 .024	 .085	 .158	 .080	 .134	 .106	 -.066	 .124	 .056	
CRP	 .153	
 
.032	 .235	 .043	 .236	 .026	 .022	 .349	 .076	 .333	 .181	 -.113	 .371	 .092	
IL-4	 .055	 .032	
 
.365	 .393	 .179	 .250	 .580	 .313	 .124	 .003	 -.006	 -.038	 .029	 .010	
IL-6	 .051	 .235	 .365	
 
.306	 .276	 .581	 .611	 .460	 .107	 .103	 -.025	 -.034	 .123	 .020	
IL-10	 .046	 .043	 .393	 .306	
 
.070	 .232	 .448	 .201	 .045	 -.002	 -.019	 -.076	 -.016	 .062	
VEGF	 .072	 .236	 .179	 .276	 .070	
 
.146	 .202	 .401	 .247	 .232	 .133	 .031	 .100	 .058	
TNF-α	 .024	 .026	 .250	 .581	 .232	 .146	
 
.438	 .250	 .079	 .014	 .003	 -.006	 .002	 .036	
IL-1β	 .085	 .022	 .580	 .611	 .448	 .202	 .438	
 
.411	 .112	 -.013	 -.003	 -.035	 .027	 .022	
IL-1RA	 .158	 .349	 .313	 .460	 .201	 .401	 .250	 .411	
 
.377	 .378	 .256	 -.005	 .264	 .037	
MCP-1	 .080	 .076	 .124	 .107	 .045	 .247	 .079	 .112	 .377	
 
.276	 .339	 .164	 .010	 .005	
WBC	 .134	 .333	 .003	 .103	 -.002	 .232	 .014	 -.013	 .378	 .276	
 
.346	 -.032	 .141	 .039	
TGL	 .106	 .181	 -.006	 -.025	 -.019	 .133	 .003	 -.003	 .256	 .339	 .346	
 
-.121	 .117	 .171	
Adiponectin	 -.066	 -.113	 -.038	 -.034	 -.076	 .031	 -.006	 -.035	 -.005	 .164	 -.032	 -.121	
 
-.045	 -.106	
BMI	 .124	 .371	 .029	 .123	 -.016	 .100	 .002	 .027	 .264	 .010	 .141	 .117	 -.045	
 
.054	
HbA1c	 .056	 .092	 .010	 .020	 .062	 .058	 .036	 .022	 .037	 .005	 .039	 .171	 -.106	 .054	
 



























PHQ-9 score was entered as the dependent variable. Values of ‘B’, ‘standardised-b’ and ‘p’ presented here relate to the regression of column heading and PHQ-9 score. 
*significant after Simes’ improved Bonferroni correction for multiple testing. †Adjusted for age, gender, ethnicity, HbA1c, BMI, smoking, history of macrovascular disease (MVD) 
and prescribed medications. Only age, gender, BMI and MVD and Smoking are displayed here as these were the explanatory covariates. ‡These variables were ln transformed 
Table 3.6: Adjusted† final multiple linear regression models for the independent association between PHQ-9 score‡ and each inflammatory marker‡ 
Model R2 Inflammatory marker Age Gender BMI MVD Smoking 












0.25 (0.09) 0.31 (0.07) 
standardised-b 0.07 0.13 
P 0.008* <0.001* 
VEGF 
 












0.19 (0.10) 0.32 (0.07) 
standardised-b 0.06 0.13 
P 0.048 <0.001* 
IL-1β 
 












0.20 (0.10) 0.32 (0.07) 
standardised-b 0.06 0.13 
P 0.043 <0.001* 












0.17 (0.10) 0.29 (0.07) 
standardised-b 0.05 0.12 
P 0.082 <0.001* 












0.19 (0.10) 0.31 (0.07) 
standardised-b 0.06 0.13 
P 0.052 <0.001* 












0.22 (0.09) 0.32 (0.07) 
standardised-b 0.07 0.13 
P 0.014* <0.001* 












0.22 (0.09) 0.33 (0.06) 
standardised-b 0.07 0.14 
P 0.011* <0.001* 













0.26 (0.09) 0.34 (0.07) 



















































































































































































































































































































































































































Table 4.1: Baseline characteristics of participants with type 2 diabetes mellitus in the South 
London Diabetes Study with a PHQ-9 score at baseline stratified by whether subjects also had 
a complete set of inflammatory markers assayed 
Baseline variable Total 
(n = 1769) 
All Tests 
Complete 
(n = 1083) 
Missing Tests 
(n = 686) 
p-value 
Mean age, years 56.1 (11.04) 57 (11.04) 55 (11.04) <0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 606 (56.0) 370 (53.9) 0.405 
793 (44.8) 477 (44.0) 316 (46.1) 
     




878 (49.6) 587 (54.2) 291 (42.4) <0.001* 
710 (40.1) 385 (35.5) 325 (47.4) 
181 (10.2) 111 (10.2) 70 (10.2) 
     
HbA1c     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Psychological assessment      
PHQ-9 score 3.0 (0.0-6.0) 2.0 (0.0-6.0) 3.0 (0.0-6.0) 0.029* 
PHQ-9 depression (%) 258 (14.6) 150 (13.9) 108 (15.7) 0.272 





Table 4.2: Characteristics of 1083 depressed (PHQ-9≥ 10) and non-depressed (PHQ-9 < 10) 
subjects with type 2 diabetes mellitus in the South London Diabetes Cohort Study for whom a 
complete set of inflammatory markers were assayed 
Baseline variable Total 
(n = 1083) 
No depression  
(n = 933) 
Depression 
(n = 150) 
p-value 
Mean age, years 
 
56.8 (10.99) 57.3 (11.09) 53.9 (9.90) <0.001* 




606 (56.0) 527 (56.5) 79 (52.7) 0.382 
477 (44.0) 406 (43.5) 71 (47.3) 





587 (54.2) 506 (54.2) 81 (54.0) 0.222 
385 (35.5) 337 (36.1) 48 (32.0) 






52.7 (15.33) 52.4 (15.26) 54.3 (15.70) 0.147 
Median triglyceride,  
mmol/L 
1.40 (1.00-2.00) 1.40 (0.90-1.90) 1.50 (1.10-2.40) 0.009* 
Mean low density 
lipoprotein, mmol/L 
2.66 (0.90) 2.66 (0.88) 2.64 (0.98) 0.830 
Mean high density 
lipoprotein, mmol/L 
1.20 (0.34) 1.21 (0.33) 1.20 (0.41) 0.770 
Mean total cholesterol, 
mmol/L 
 
4.61 (1.08) 4.59 (1.04) 4.71 (1.23) 0.285 
3Mean body mass index, 
kg/m2 
 
31.8 (6.41) 31.6 (6.21) 32.9 (7.46) 0.041* 
4Macrovascular disease 
(%) 
    
None 
More than 1 
 
968(90.6) 843 (91.6) 125 (84.5) 0.005* 
100 (9.4) 77 (8.4) 23 (15.5) 
Data are n (%), mean (SD) or median (IQR) as appropriate 
*significant α=0.05 . T-test and Mann Witney U test used for normal and non-normal data 
1missing data for this variable, HbA1c values were not available for 12 cases. 
2missing data for this variable, LDL vales were not available for 89 cases, HDL values were not 
available for 57 cases and total cholesterol values were not available for 30 cases. 
3missing data for this variable, BMI values were not available for 1 case. 














































































PHQA  .666 .465 .462 .372 .509 .523 .450 .437 .100 .093 .043 .073 .078 .073 .039 .065 .028 .042 .055 
PHQB .666  .438 .454 .384 .614 .449 .436 .452 .122 .118 .047 .060 .057 .110 .021 .070 .005 .045 .043 
PHQC .465 .438  .528 .352 .389 .388 .362 .314 .156 .149 .061 .116 .096 .134 .021 .020 .032 .084 .054 
PHQD .462 .454 .528  .369 .421 .421 .359 .292 .146 .118 .036 .102 .093 .101 .059 .048 .017 .027 .025 
PHQE .372 .384 .352 .369  .350 .356 .288 .238 .109 .092 .024 .023 .095 .132 .015 .005 -.025 .007 .039 
PHQF .509 .614 .389 .421 .350  .420 .402 .453 .075 .063 -.003 .040 .065 .066 .034 .051 -.024 -.011 .008 
PHQG .523 .449 .388 .421 .356 .420  .437 .322 .080 .066 -.002 .043 .037 .032 .069 .073 .004 .010 .013 
PHQH .450 .436 .362 .359 .288 .402 .437  .353 .079 .056 .065 .064 .065 .073 .042 .051 .025 .036 .025 
PHQI .437 .452 .314 .292 .238 .453 .322 .353  .068 .098 -.009 .056 .068 .100 -.010 .000 .009 .009 .003 
IL-1RA .100 .122 .156 .146 .109 .075 .080 .079 .068  .391 .418 .388 .242 .348 .265 .134 .294 .476 .456 
WBC .093 .118 .149 .118 .092 .063 .066 .056 .098 .391  .225 .254 .300 .342 .015 -.008 .004 .081 .027 
VEGF .043 .047 .061 .036 .024 -.003 -.002 .065 -.009 .418 .225  .271 .116 .215 .164 .073 .193 .262 .228 
MCP-1 .073 .060 .116 .102 .023 .040 .043 .064 .056 .388 .254 .271  .298 .075 .095 .068 .052 .100 .146 
TGL .078 .057 .096 .093 .095 .065 .037 .065 .068 .242 .300 .116 .298  .131 -.016 .020 .000 -.013 .012 
CRP .073 .110 .134 .101 .132 .066 .032 .073 .100 .348 .342 .215 .075 .131  .035 .055 .020 .120 -.009 
IL-4 .039 .021 .021 .059 .015 .034 .069 .042 -.010 .265 .015 .164 .095 -.016 .035  .436 .271 .363 .545 
IL-10 .065 .070 .020 .048 .005 .051 .073 .051 .000 .134 -.008 .073 .068 .020 .055 .436  .175 .208 .383 
TNF-α .028 .005 .032 .017 -.025 -.024 .004 .025 .009 .294 .004 .193 .052 .000 .020 .271 .175  .695 .496 
IL-6 .042 .045 .084 .027 .007 -.011 .010 .036 .009 .476 .081 .262 .100 -.013 .120 .363 .208 .695  .740 
IL-1β .055 .043 .054 .025 .039 .008 .013 .025 .003 .456 .027 .228 .146 .012 -.009 .545 .383 .496 .740  






















The factor order (percentage of variance explained) was ‘cytokine 1’ (23.0%), ‘PHQ-9 1’ (16.2%), 





Table 4.4: Pattern matrix of depressive symptoms and inflammatory markers after factor 
analysis  
Depressive Symptoms & Inflammatory 
Markers 
















Depressed mood 0.90 -0.07 0.01 0.03 0.01 
Feelings of worthlessness or guilt 0.68 0.05 -0.05 -0.02 0.04 
Anhedonia 0.65 0.17 0.01 -0.02 0.04 
Suicidal ideation or thoughts of death  0.57 -0.01 0.01 0.03 -0.04 
Psychomotor agitation or retardation  0.35 0.27 0.02 -0.02 0.02 
Fatigue or loss of energy  -0.01 0.73 -0.01 0.02 0.02 
Insomnia or hypersomnia -0.01 0.69 0.08 0.05 -0.05 
Diminished ability to concentrate 0.28 0.40 -0.02 -0.06 0.06 
Loss of appetite 0.18 0.36 -0.02 0.04 0.14 
IL-6 0.01 0.03 0.99 0.05 0.01 
TNF-α -0.03 0.04 0.70 -0.03 0.02 
IL-1β 0.01 -0.22 0.52 0.06 0.50 
IL-1RA 0.01 0.01 0.25 0.68 0.15 
WBC 0.04 0.01 -0.02 0.59 -0.10 
MCP-1 -0.04 0.04 -0.07 0.49 0.12 
CRP 0.06 0.01 0.07 0.44 -0.13 
VEGF 0.02 -0.07 0.13 0.44 0.08 
TGL -0.02 0.05 -0.11 0.42 -0.01 
IL-10 0.06 -0.03 -0.03 0.03 0.68 








Table 4.5 Table showing correlations between the five extracted factors 
 P1 P2 C1 C2 C3 
P1 1.000 .762 .001 .139 .047 
P2 .762 1.000 -.009 .218 .057 
C1 .001 -.009 1.000 .192 .408 
C2 .139 .218 .192 1.000 .107 
C3 .047 .057 .408 .107 1.000 
Correlation coefficients range from .000 (no correlation) to 1.00 (perfect correlation) 
Table 4.6: Unadjusted Spearman’s ranked correlations for the independent association between 
inflammation indices or inflammatory marker concentration and PHQ-9 score 
 
Composite inflammation indices rs p-value 
Cytokine Index 1 (IL-6, IL-1β, TNF-α) 0.09   0.005* 
Cytokine Index 2 (CRP, IL-1RA, WBC, MCP-1, VEGF, TGL) 0.19 <0.001* 
Cytokine Index 3 (IL-4, IL-10, IL-1β) 
 
0.10   0.001* 
Individual inflammatory marker   
CRP  0.12 <0.001* 
IL-4  0.08   0.013* 
IL-6  0.06   0.047 
IL-10  0.07   0.029* 
VEGF  0.08   0.013* 
TNF-α  0.04   0.175 
IL-1β  0.10   0.002* 
IL-1RA  0.17 <0.001* 
MCP-1  0.10   0.001* 
WBC  0.14 <0.001* 
TGL  0.09   0.002* 



























Table 4.7: Adjusted1 final multiple linear regression models for the independent association 
between PHQ-9 score2 and each inflammatory marker2 or inflammatory score 
Model R2  
Cytokine Index 1  
(IL-6, IL-1β, TNF-α) 
 






Cytokine Index 2  
(CRP, IL-1RA, WBC, MCP-1, VEGF, 
TGL) 
0.09 B (SE) 0.04 (0.01) 
 standardised-b 0.17 
 p <0.001* 
Cytokine Index 3  
(IL-4, IL-10, IL-1β) 
 
0.07 B (SE) 0.03 (0.01) 
 standardised-b 0.07 
 p 0.028* 





IL-4 0.07 B (SE) 0.26 (0.12) 
  standardised-b 0.07 
  p 0.029* 
IL-10 0.06 B (SE) 0.15 (0.10) 
  standardised-b 0.05 
  p 0.133 
VEGF 
 
































1adjusted for age, gender, ethnicity, HbA1c, BMI, smoking, history of macrovascular disease (MVD) 
and prescribed medications. 2These variables were ln transformed 
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Table 5.1: Baseline characteristics of participants with type 2 diabetes mellitus in the South 
London Diabetes Study with a PHQ-9 score at baseline stratified by whether there was a 
frozen serum sample at follow-up for subjects 
Baseline variable Total 
(n = 1769) 
Analyses 
Group 
(n = 1020) 
Non Analyses 
Group 
(n = 749) 
p-value 
Mean age, years 56.1 (11.04) 57.33 (10.59) 54.41 (11.40) <0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 567 (55.6) 409 (54.6) 0.168 
793 (44.8) 453 (44.4) 340 (45.4) 
     




878 (49.6) 545 (53.4) 333 (44.5) <0.001* 
710 (40.1) 372 (36.5) 338 (45.1) 
181 (10.2) 103 (10.1) 78 (10.4) 
     
HbA1c     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Psychological assessment     
Median PHQ-9 score 3.0 (0.0-6.0) 2.0 (0.0-6.0) 3.0 (0.0-7.0) 0.324 
PHQ-9 depression (%) 258 (14.6) 139 (13.6) 119 (15.9) 0.183 




























Table 5.2: Characteristics of participants with type 2 diabetes mellitus in the South London 
Diabetes Study at baseline and 12 months after diagnosis stratified by baseline PHQ-9 
depression status 
Variable Total 
(n = 1556)  
No depression at 
baseline  
(n = 1336) 
Depression at 
baseline 
(n = 220) 
p-value 
Baseline mean age, 
years 
56.5 (10.95) 57.0 (11.02)  53.35 (9.98) <0.001* 
     
Gender (%)     
Male 
Female 
857 (55.1) 753 (56.4) 104 (47.3) 0.012* 
699 (44.9) 583 (43.6) 116 (52.7) 
     




793 (51.0) 684 (51.2) 109 (49.5) 0.062 
605 (38.9) 526 (39.3) 79 (35.6) 
158 (10.2) 126 (9.4) 32 (14.5) 
     





























     
Body mass index     
Baseline 























    
None 1391 (90.5) 1204 (91.3) 186 (85.7) 0.010* 
More than 1 146 (9.5) 115 (8.7) 31 (14.3) 
12-month     
None 1302 (88.6) 1129 (89.5) 173 (82.8) 0.004* 
More than 1 168 (11.4) 
 
132 (10.5) 36 (17.2) 
Inflammatory marker     
Baseline  






















































Table 5.3: Change (Δ) in characteristics of participants with type 2 diabetes mellitus in the South 
London Diabetes Study between baseline and 12 months follow-up, stratified by baseline PHQ-9 
depression status. 
Variable Total 




(n = 881) 
Depression case 
subject at 
baseline (n = 139) 
p-value 









Median ΔBMI, kg/m2 0.02 (-1.00-1.10) 0.10 (-0.98-1.10) 0.00 (-1.37-1.01) 0.185 
     
New macrovascular 
event (%) 
17 (1.7) 15 (1.7) 2 (1.4) 0.823 
     
Median Δ TGL, mmol/L 0.00 (-0.3-0.3) 0.00 (-0.3-0.3) -0.10 (-0.4-0.30) 0.083 
Median Δ CRP, mg/L 0.20 (-1.70-0.60) -0.20 (-1.80-0.60) -0.10 (-1.60-0.80) 0.215 
     
Mean Δ PHQ-9 Score -0.47 (4.34) 0.28 (3.45) -5.00 (6.11) <0.001* 
     
* significant after Simes’ improved Bonferroni correction for multiple testing 
 
Table 5.4: Adjusted† final multiple linear regression models for the independent association between two inflammatory markers at 12-month follow-up‡ and 
PHQ-9 score at baseline‡ n = 1020 
Model R2  PHQ-9 Age Gender Ethnicity HbA1c BMI MVD Smoking 









-0.14 (0.05) 0.006 (0.002) 0.04 (0.004) 
0.34 
<0.001* 
0.11 (0.08) 0.16 (0.56) 
standardised-b -0.09 0.11 0.04 0.09 
p 0.003* <0.001* 0.163 0.004* 









-0.23 (0.02) 0.001 (0.001) 0.004 (0.002) 
0.06 
0.042 
-0.02 (0.04) 0.13 (0.03) 
standardised-b -0.32 0.04 -0.02 0.15 
p <0.001 0.253 0.644 <0.001 
*significant after Simes’ improved Bonferroni correction for multiple testing. †Adjusted for age, gender, ethnicity, HbA1c, BMI, smoking, history of 
macrovascular disease (MVD) and prescribed medications at baseline. Only age, gender, ethnicity, HbA1c, BMI MVD and smoking are displayed here as these 
were the explanatory covariates. ‡These variables were ln transformed 
 
 
Table 5.5: Adjusted† final multiple linear regression models for the independent association between inflammatory markers at 12-month follow-up‡ and 
PHQ-9 score at baseline‡, after adjusting for baseline inflammation‡ n = 1020 
Model R2  PHQ-9 Marker at Baseline Gender Ethnicity BMI MVD 












0.017 (0.003) 0.10 (0706) 
standardised-b 0.14 0.04 
p <0.001* 0.121 












0.001 (0.001) -0.05 (0.03) 
standardised-b 0.01 -0.04 
p 0.722 0.068 
*significant after Simes’ improved Bonferroni correction for multiple testing. †Adjusted for markers at baseline, age, gender, ethnicity, HbA1c, BMI, smoking, 
history of macrovascular disease (MVD) and prescribed medications. Only marker at baseline, age, gender, ethnicity, BMI and MVD are displayed here as these 





































Graph to show unadjusted change in CRP depending on PHQ-9 
depression case status at baseline and 12 month follow-up (n =1020)
Depressed Baseline, Non-depressed Year 1 (n=
71)
Depressed at Baseline and Year 1 (n= 68)
Not-depressed baseline, became Depressed at
Year 1 (n= 59)





































Table 5.6. Adjusted† Marginal Means from ANCOVA models for change in mean CRP at 12-
month follow-up stratified by PHQ-9 depression status at baseline and 12-month follow-up 








change in CRP 
(mg/L) 
p-value 
ANCOVA A    
Non-depressed subjects -0.75 1.327 0.002* 
Depression cases at year 1 0.58 
ANCOVA B    
Depression cases at baseline only 0.14 0.445 0.238 
Depression cases at baseline and year 1 -0.30 
    
†Adjusted for baseline age, gender, ethnicity, HbA1c, macrovascular disease, smoking, 
prescription of medication BMI and any stressful life events between baseline and 12-month 
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ADJUSTED MARGINAL MEAN CHANGE IN CRP (MG/L)
Figure 5.3: Graph to show adjusted marginal means from ANCOVA A and ANCOVA B
Depression Cases at Baseline and Year 1 Depression Cases Baseline Only Depression Cases Year 1 Non-depressed Subjects
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Table 5.7. CRP concentration as a risk factor for cardiovascular disease risk 
CRP > 1 mg/L > 2 mg/L > 3 mg/L 
Cardiovascular 
disease risk 

















































































































































































































































Table 6.1:  Characteristics of participants with type 2 diabetes mellitus in the South London 
Diabetes Study who had a PHQ-9 score at baseline stratified by whether there was a PHQ-9 
score at follow-up for subjects  
Baseline variable Total 
(n = 1769) 
Complete PHQ-9 
(n = 1361) 
Missing PHQ-9  
(n = 408) 
p-value 
Mean age, years 56.1 (11.04) 57.01 (11.74) 53.05 (11.45) <0.001* 
     
Gender (%)     
Male 
Female 
976 (55.2) 766 (56.3) 221 (51.5) 0.087 
793 (44.8) 595 (43.7) 208 (8.5) 
     




878 (49.6) 720 (52.9) 158 (38.7) <0.001* 
710 (40.1) 506 (37.2) 204 (50.0) 
181 (10.2) 135 (9.9) 46 (11.3) 
     
HbA1c     
Mean % HbA1c 
Mean HbA1c, mmol/mol 







     
Psychological 
Assessment  
    
PHQ-9 Score 3.0 (0.0-6.0) 3.0 (0.0-6.0) 3.0 (0.0-8.0) 0.318 
PHQ-9 depression (%) 258 (14.6) 187 (13.7) 71 (17.4) 0.066 

















Table 6.2: Unadjusted Spearman’s ranked correlation for association between inflammatory 
marker concentration at baseline and PHQ-9 score at 12-month follow-up 
 
Inflammatory marker rs p-value 
Inflammation Score (Cytokine Index 2) 0.12 <0.001* 
CRP 0.12 <0.001* 
IL-4  0.05   0.097 
IL-6  0.08   0.801 
IL-10  0.03   0.397 
VEGF  0.07   0.032 
TNF-α  -0.001   0.987 
IL-1β  0.03   0.345 
IL-1RA  0.09   0.006* 
MCP-1  0.06   0.053 
WBC  0.05   0.085 
TGL  0.10 <0.001* 
Adiponectin -0.06   0.028 



































Table 6.3: Adjusted† final multiple linear regression models for the independent association between PHQ-9 score‡ at 12-month follow-up and each 
inflammatory marker‡ at baseline  
 
Model R2 Inflammatory marker Age Gender BMI MVD SLE Smoking 





















































































































































1 Composite score of the sum of the z-scores of CRP, IL-1RA, WBC, MCP-1, VEGF and TGL at baseline based on factor analysis (Chapter 4). 
*significant after Simes’ improved Bonferroni correction for multiple testing 
†adjusted for age, gender, ethnicity, HbA1c, BMI, smoking, history of macrovascular disease (MVD) and prescribed medications (baseline) and stressful 
life events between baseline and 12 months. 
Only age, gender, BMI, MVD and Stressful Life Events (SLE) are displayed here as these were the explanatory covariates. 
‡these variables were ln transformed 
#MCP-1 was trending close to significance in the unadjusted Spearman’s correlation and was associated with depression score at baseline so was 




Table 6.4: Adjusted† final multiple linear regression models for the independent association between PHQ-9 score‡ at 12-month follow-up and each 




Inflammatory marker PHQ-9 Baseline Age MVD SLE Smoking 
































































































































1 Composite score of the sum of the z-scores of CRP, IL-1RA, WBC, MCP-1, VEGF and TGL at baseline based on factor analysis (Chapter 4). 
*significant after Simes’ improved Bonferroni correction for multiple testing 
†adjusted for age, gender, ethnicity, HbA1c, BMI, smoking, history of macrovascular disease (MVD) and prescribed medications (baseline), stressful life 
events between baseline and 12 months and PHQ-9 score at baseline. 
Only PHQ-9 at baseline, age, MVD and Stressful Life Events (SLE) are displayed here as these were the explanatory covariates. 
‡these variables were ln transformed 







Table 6.5: Incidence of PHQ-9 depression cases at 12-month follow-up (in participants who were 
non-depressed subjects at baseline, n = 789) stratified by baseline Systemic Inflammation Score 
Variable Total 








(n = 387) 
p-value 
Baseline mean age, years 57.6 (11.0) 56.8 (11.4) 58.4 (10.6) 0.043* 
     
Gender (%)     
Male 
Female 
453 (57.4) 220 (54.7) 233 (60.2) 0.120 
326 (42.6) 182 (45.3) 154 (39.8) 
     




438 (55.5) 152 (37.8) 286 (73.9) <0.001* 
274 (34.7) 218 (54.2) 56 (14.5) 
77 (9.8) 32 (8.0) 45 (11.6) 
     
HbA1c     
Baseline  
























    
Body Mass Index  
    
Baseline 



















     
Baseline macrovascular disease 
(%) 
    
None 716 (91.9) 380 (95.5) 336 (88.2) <0.001* 
More than 1 63 (8.1) 18 (4.5) 45 (11.8)  
     
Baseline-12-month stressful life 
events  
    
None 504 (65.7) 263 (67.3) 241 (64.1) 0.356 




   
 
Incident Depression Cases (%) 47 (6.0) 21 (5.2) 26 (6.7) 0.375 
*significant α=0.05. T-test and Mann Witney U test used for normal and non-normal data  
Missing or incomplete values for: HbA1c (12 month) = 7 (29) cases, BMI (12 month) = 1 (5) cases, 
macrovascular history = 10 cases, stressful life events = 22 cases. 
Low inflammation scores were scores that were below the mean score at baseline and high 
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Percentage	 HbA1c	was	measured	 using	 Primus	 Ultra2	 boronate	 affinity	 HPLC.	
The	Ultra2	is	manufactured	by	Primus	Corporation,	4231	E.	7th	Terrace,	Kansas	




Whole	 blood	 specimens	 are	 required	 for	 measurement	 of	 HbA1c.	 EDTA	 and	
fluoride	 oxalate	 are	 suitable	 anticoagulants	 and	were	 used	 for	measurement	 of	
HbA1c	for	this	study.	Samples	were	collected	in	2ml	fluoride	oxalate	or	3ml	EDTA	
vacutainers	or	capillary	tubes.	Samples	were	analysed	on	the	day	of	venepuncture	




Glycated	 haemoglobin	 is	 formed	 by	 the	 attachment	 of	 a	 sugar	 molecule	 to	 the	
binding	site	of	haemoglobin	by	a	ketoamine	bond.	1,2–cis-diol	groups	are	formed	
in	 this	 process	 and,	 as	 these	 1,2–cis-diol	 groups	 are	 not	 found	 in	 non-glycated	
haemoglobin,	 provide	 the	 basis	 for	 separation	 of	 glycated	 and	 non-glycated	
components	 of	 haemolysate	 (lysed	 red	 blood	 cells)	 by	 boronate	 affinity	
chromatography.	 In	 the	 technique	 a	 boronate	 (in	 this	 case	 aminophenylboronic	
acid)	is	bonded	to	the	surface	of	a	column.	When	haemolysate	is	passed	through	
the	column,	the	diol	groups	of	glycated	haemoglobin	complex	with	the	boronate	
and	 cause	 it	 to	 remain	 in	 the	 column.	The	non-glycated	 component	 elutes	 from	
the	 column.	 Finally,	 the	 glycated	 component	 is	 eluted	 from	 the	 column	 with	 a	
reagent	that	displaces	it	from	the	boronate.	
	
The	 Primus	 Ultra2	 system	 setup	 consisted	 of	 four	 main	 components	 used	 to	
fractionate	and	quantitate	HbA1c:	
1. The	 Ultra2	 boronate	 affinity	 HPLC	 (composed	 of	 a	 dual	 high-
pressure	 pump	 system,	 column	 oven	 and	 variable	 wavelength	
detector).	
2. The	Gilson	215	auto-sampler	is	able	to	handle	285	samples	during	a	
single	 batch	 run,	 with	 the	 ability	 to	 accommodate	 a	 variety	 of	
sample	tubes	with	corresponding	rack	types.	







The	 Primus	 Ultra2	 combines	 the	 principles	 of	 boronate	 affinity	 and	 high	
performance	 liquid	 chromatography.	 Low	 and	 high-pressure	 pumps	 transfer	
reagents	 through	 an	 analytical	 column.	 The	 analytical	 column	 contains	
aminophenylboronic	acid	bonded	to	a	porous	polymer	support.	The	haemolysate	
is	 automatically	 injected	 onto	 the	 column	 during	 the	 flow	 of	 reagent	 A.	 The	
glycated	 haemoglobin	 binds	 to	 the	 aminophenylboronic	 acid,	 while	 the	 non-
glycated	 haemoglobin	 passes	 through	 the	 column	 to	 the	 spectrophotometric	
detector,	 where	 it	 is	 detected	 at	 a	 wavelength	 of	 413	 ±	 2	 nm.	 After	 complete	
elution	 of	 the	 non-glycated	 haemoglobin,	 the	 pump	 switches	 to	 reagent	 B,	 this	
displaces	 the	glycated	haemoglobin	and	passes	 through	 the	detector	where	 it	 is	
detected	at	the	same	wavelength.	To	ensure	a	stable	baseline	the	composition	of	
the	 two	 reagents	 has	 been	 designed	 so	 that	 they	 exhibit	 virtually	 identical	
absorption.	 The	 detector	 signal	 is	 also	 referenced	 against	 a	 photodiode	 by	 the	
split	 beam	 technique.	 Finally,	 the	 column	 is	 re-equilibrated	with	 reagent	A.	The	



























Advia	 2400	 is	 manufactured	 by	 Siemens	 Healthcare	 Diagnostics	 Ltd,	 Newton	



































































































































































































anticoagulants	 and	were	 used	 for	measurement	 of	 FBC	 for	 this	 study.	 Samples	
were	 collected	 in	 3ml	 EDTA	 vacutainers.	 Samples	were	 analysed	 on	 the	 day	 of	
































































    
     















SOUL-D ID No.:  
 
 
Researcher ID:  
 
 








0.1 Participant NHS number:             
 
0.2 GP national code number:        
 
0.3 GP surgery: ………………………………… 
 
0.4 GP address:………………………………………………………………….. 
 
0.5 Laboratory site (bloods etc), please tick:  
1 KCH      2 GSTT      3 PRU     4 UHL     5 QMS     6 Mayday 
7 Other………….. 
 
0.6 GP borough 
1 Lambeth  2 Southwark 3 Lewisham 4 Bromley  
5 Other…………… 
 
Entry Visit Checklist 
PIS given to participant       Yes   No 
Original consent to study files      Yes   No 
Copy of consent to participant      Yes   No 
Copy of consent to GP       Yes   No 
0.7 Baseline questionnaire completed   1 Yes 2 No 
0.8 Baseline bloods completed    1 Yes 2 No 
0.9 Baseline CRF completed    1 Yes 2 No 
0.10 Researcher Notes 
a. Questionnaire booklet read to subject?  1 Yes 2 No 
b. If yes, because of: 1 Vision problem 2 Literacy   3 Other …………  
0.11 Year 1 Visit Checklist 
a. Consent reviewed with participant: 
1Yes  2Refused    3Non-contactable  
b. Questionnaire completed    1 Yes 2 No 
c. Year 1 bloods completed    1 Yes 2 No 
d. Year 1 CRF completed     1 Yes 2 No 
0.12 Year 2 Visit Checklist 
a. Consent reviewed with participant:  
1Yes  2Refused    3Non-contactable  
b. Questionnaire completed    1 Yes 2 No 
c. Year 2 bloods completed    1 Yes 2 No 
d. Year 2 CRF completed     1 Yes 2 No 
1.0 Date of data collection   




1. Socio-demographics data 
 
1.1 Date of birth       




1  Male 
2  Female           
 
1.3 What is your legal partnership status? 









1.4 Have you had children? 
1  Yes    If yes, please list how many______ 
2  No 
 
1.5 What is your ethnic group?  
Choose ONE section from a. to e., then tick the appropriate box to indicate 
your ethnic group. 
 
a. White 
1 British           
2 Irish 
3 Any Other White background, please write in 
……………………………………            
 
b. Mixed 
4 White and Black Caribbean 
5 White and Black African 
6 White and Asian 
7 Any Other Mixed background, please write in 
…………………………………. 
 




11 Any Other Asian background, please write in 
…………………………………. 
 





14 Any Other Black background, please write in 
………………………………….. 
  
e. Chinese or other ethnic group 
15 Chinese 
16 Any Other, please write in 
……………………………………………………… 
 
1.6 What is your country of birth? 
 
1 England 
2 Elsewhere, please write in the present name of the country 
………………… 
 




1.8 Do you attend a formal congregation or religious group? 
1 Yes      
 If yes, list group ________________________ 
2 No 
 
1.9 Employment status 
 
Are you currently…. 
 
1 In full-time employment 
2 In part-time employment 
3 On sick leave 
4 Unemployed 
5 Medically retired 
6 A housewife/husband 
7 Retired 
 
The following questions refer to your current main job, or (if you are not 
working now) to your last main job.  Please tick one box only per question. 
 
1.10 Employee or self-employed 
Do (did) you work as an employee or are (were) you self-employed? 
1 Employee 
2 Self-employed with employees 









1.11 Number of employees 
For employees:  Indicate below how many people work (worked) for your 
employer at the place where you work (worked). 
 
For self-employed:  Indicate below how many people you employ (employed).  
Go to question 1.13 when you have completed this question. 
 
Please tick box. 
 
1 1 to 24 
2 25 or more 
 
1.12 Supervisory status 
Do (did) you supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other 






Please tick one box to show which best describes the sort of work you do. 
(If you are not working now, please tick a box to show what you did in your 
last job). 
 
PLEASE TICK ONE BOX ONLY. 
 
 1 Modern professional occupations 
Such as:  teacher, nurse, physiotherapist, social worker, welfare officer, artist, 
musician, police officer (sergeant or above), software designer 
 
2 Clerical and intermediate occupations 
Such as:  secretary, personal assistant, clerical worker, office clerk, call centre 
agent, nursing auxiliary, nursery nurse 
 
3 Senior mangers or administrators 
(usually responsible for planning, organising, and co-ordinating work and for 
finance) 
Such as:  finance manager, chief executive 
 
4 Technical and craft occupations 
Such as: motor mechanic, fitter, inspector, plumber, printer, tool maker, 
electrician, gardener, train driver 
 
5 Semi-routine manual and service occupations 
Such as:  postal worker, machine operative, security guard, caretaker, farm 






6 Routine manual and service occupations 
Such as:  HGV driver, van driver, cleaner, porter, packer, sewing machinist, 
messenger, labourer, waiter / waitress, bar staff 
 
7 Middle or junior managers 
Such as:  office manager, retail manager, bank manager, restaurant manager, 
warehouse manager, publican 
 
8 Traditional professional occupations 
Such as:  accountant, solicitor, medical practitioner, scientist, civil / 
mechanical engineer 
 
1.14 What is your current (or last) job title? 
 Please write in: …………………………………………………………. 
 




2. Diabetes history 
 
2.1 Date of T2DM diagnosis      









2.3 Mode of Onset: 
 
1 Diabetic Symptoms 
2 Routine/screening blood or urine test and symptoms 
3 Routine/screening blood or urine test, no symptoms 
4 Ketoacidosis (proven) i.e. African patients 
5 Non-ketotic hyperosmolar (proven) 
6 Ketones present (not DKA) 
7 Diagnosed during pregnancy 
8 Not known 
 
2.3 Have you attended structured diabetes education? (e.g. DESMOND) 
   
1 Yes 
 if yes, date (mm/yy)____/____ 
2 No 





2.4 Physical examination at diagnosis: 
 
Measurement Units Value Month/year (mm/yy) 
a. Height cm   
b. Weight kg   
c. BMI wt/ht2   
d. Blood pressure systolic  mmHg   
e. Blood pressure diastolic  mmHg   
 
2.5 Lab tests at diagnosis: 
 
Test Units Value Month/year (mm/yy) 
a. Triglycerides  mmol/L   
b. LDL  mmol/L   
c. HDL mmol/L   
d. Total cholesterol mmol/L   
e. HbA1c %   
 




2.6.1 Microalbuminuria (ACR):  
  
 a. Sample collection: 
1 Data not available (continue to 2.6.2) 
2 Early morning urine 
3 Random sample 
4 Not indicated 
 
 b. Results: 
1 Negative (ACR < 3) 
2 Positive (ACR ≥ 3) 
       
2.6.2 Proteinuria (urine dipstick) 
  
 a. Sample Collection: 
1 Data not available (continue to 2.6.3) 
2 Early morning urine 
3 Random sample 
4 Not indicated 
 
 b. Results: 
1 Negative (0 – trace on urine dipstick) 
2 Positive (1+ - 3+ on urine dipstick) 









2.6.3 Attended DECS 
1 Yes  
2 No 
3 Appointment booked (date: ___ ___ /___ ___ / ___ ___ (dd/mm/yy)) 
4 No appointment booked 
 
2.6.4 DECS coding 
1 No retinopathy 
2 Treated retinopathy 
(laser, photocoagulation, vitrectomy, quiescent retinopathy) 
3 Non-sight threatening retinopathy 
(background, mild/minimal pre-proliferative, mild/moderate non-proliferative) 
4 Sight-threatening retinopathy 
(maculopathy, moderate/severe pre-proliferative, pre-proliferative and 
maculopathy, non-proliferative maculopathy, at risk of and with clinically 
significant macula oedema) 
 
     2.6.4 Date of DECS assessment: ___ ___ / ___ ___ (mm/yy) 
 
2.6.5 Laser treatment 
1 Yes  
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
2 No 
 
2.6.6  Cataracts 
1 Yes  
2 No 
      
2.6.6 Registered partially sighted, secondary to diabetes 
1 Yes 
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
2 No 
       
Feet: 
 
Foot ulcers/history of ulcer 


























2.6.12 Carotid revascularisation 
1 Yes        
If yes, date:  ___  ___ / ___ ___ (mm/yy) 
2 No 
 
2.6.13 Limb revascularisation  
1 Yes        




1 Yes        
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
 If yes: 2 Major 
  1 Minor 
2 No 
 
2.6.15 Erectile dysfunction (see recruiter booklet for explanation) 





2.6.16 Severe hypoglycaemia (needing 3rd party assistance, see recruiter 










2.7 QOF psychological assessment at diagnosis: 
 
2.7.1 Completion of QOF 2-item depression screening 
1 Yes     
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
2 No 
 
2.7.2 Results: Positive depression screen  
1 Yes 
2 No (if no, go to section 3) 
 
2.7.3 If positive screen, full depression screen completed?  (e.g. PHQ-9, 
HADS) 
1 Yes        
If yes, date: ___ ___ / ___ ___ (mm/yy) 
2 No 
 
2.7.4 If positive screen, any management for depression? 
1 Self-help (e.g. book/leaflet)        
2 Anti-depressant 
3 Counselling      
4 CBT 
5 Diabetes specific psychological treatment (e.g. MET/MI for diabetes) 





3. Current depression 
 
Depression (CIS-R) 
Interviewer: please tick box 






3.2 During the past month, have you been able to enjoy or take an interest in 
things as much as you usually do? 
1 Yes    
2 No 
 







4. Current physical/psychological status (QOF screen=grey boxes) 
Date of assessment _ _/_ _/_ _ 
 
Physical examination: 
 Units Value 
a. Height  cm  
b. Seated height  cm  
c. Leg length  difference a-b  
d. Weight  kg  
e. BMI  wt/ht2  
f. Waist circumference  cm  
g. Blood pressure systolic  mmHg  
h. Blood pressure diastolic  mmHg  
 
Neuropathy assessment: 
 Units Value 
Vibration Perception Threshold   
4.1   R 1st toe    volts  
4.2   L 1st toe    volts  
10g monofilament sensation   
Test 5 sites: 1st, 2nd, 3rd, & 5th plantar metatarsal heads and plantar 
aspect of great toe.  If feels < 3/5, abnormal result. 
4.1  R foot      no. of sites /5 
4.2  L foot      no. of sites /5 
  
Foot pulses: 
4.3  R foot dorsalis pedis 1  Present 
2  Absent  
4.4  R foot posterior tibial 1  Present 
2  Absent  
4.5  L foot dorsalis pedis 1  Present 
2  Absent  
4.6  L foot posterior tibial 1  Present 
2  Absent  
 
Depression screening: 
Low mood – use answer from 3.1 1  Yes 
2  No 
  
Loss of interest in activities – use answer from 3.2 1  Yes 
2  No 
  
4.9 Positive screen (if yes to either of the above) 1  Yes 
2  No 
  




          
5. Current cognitive status 
 
Telephone Interview for Cognitive Status (TICS-M) 
Orientation 



























5.5 What is your telephone number (including code)? 







5.6 I’m going to read you a list of 10 words. Please listen carefully and try to      
remember them.  When I am done, tell me as many as you can in any order.  
Ready?  
 
(Read words from list below). 
 
Now, tell me all the words you can remember. 
Yes No 
1 2 Cabin 
1 2 Pipe 
1 2 Elephant 
1 2 Chest 
1 2 Silk 
1 2 Theatre 
1 2 Watch 
1 2 Whip 
1 2 Pillow 
1 2 Giant 
 
Attention/Calculation 































Comprehension, semantic & recent memory 










5.11 Who is the reigning monarch? 




5.12 Who is the Prime Minister now? 










5.14 Please say this, ‘Methodist Episcopal’. 




5.15  Please repeat the list of 10 words I read earlier. 
Yes No 
1 2 Cabin 
1 2 Pipe 
1 2 Elephant 
1 2 Chest 
1 2 Silk 
1 2 Theatre 
1 2 Watch 
1 2 Whip 
1 2 Pillow 









Interviewer:    
I want you to read slowly down this list of words starting here.  (Hand patient 
NART word list and indicate CHORD).  After each word please wait until I say 
‘next’ before reading the next word.  I must warn you that there are many 
words that you probably won’t recognise; in fact most people don’t know 
them, so just have a guess at these, O.K.?  Go ahead: 
 
Column 1 

























































































































































































































6. Medication Review / Current Treatment 
 
6.1  Herbal Remedies 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.   
b.   
c.   
d.   
e.   
f.   
 
6.2  Diabetes tablets 
1  Yes 
2  No 
 
Name Total daily dose Units  
a.  Metformin 
(Glucophage) 
  
b.  Acarbose   
c.  Repaglinide 
(Prandin) 
  
d.  Nateglinide (Starlix)   
e.  Glibenclamide 
(Daomil, Euglucon) 
  
f.  Gliclazide (Diamicron)   
g.  Glimepiride (Amaryl)   
h.  Glipizide (Glibenese, 
Minodiab) 
  






6.3  Insulin 
1  Yes 
2  No 
 
Name Dose (Units) Frequency 
a.  Insulin Lispro 
(Humalog) 
   Once daily                     Twice daily                
  Three times daily            Other: 
b.  Insulin Aspart 
(NovoRapid) 
   Once daily                     Twice daily                
  Three times daily            Other: 
c.  Insulin Glulisine 
(Apidra) 
   Once daily                     Twice daily                
  Three times daily            Other: 
d.  Insulin Glargine 
(Lantus) 
   Once daily                     Twice daily                
  Three times daily            Other: 
e.  Isophane Insulin 
(NPH) 
(eg. Insulatard, Humulin 
I) 
   Once daily                     Twice daily                
  Three times daily            Other: 
f.  Soluble Insulin 
(eg.  Humulin S, 
Actrapid) 
   Once daily                     Twice daily                
  Three times daily            Other: 
g.  Insulin Detemir 
(Levemir) 
   Once daily                     Twice daily                
  Three times daily            Other: 
h.  Humalog Mix 25    Once daily                     Twice daily                
  Three times daily            Other: 
i.  Humalog Mix 50    Once daily                     Twice daily                
  Three times daily            Other: 
j.  NovoMix 30 
(eg.  Mixtard 30) 
   Once daily                     Twice daily                
  Three times daily            Other: 
k.  Other 
Name: 
   Once daily                     Twice daily                
  Three times daily            Other: 
 
 
6.4  Cholesterol – lowering medications 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Atvorvastatin (Lipitor)   
b.  Simvastatin (Zocor)   
c.  Bezafibrate (Bezalip)   
d.  Fenofibrate (Lipantil)   
e.  Colestyramine 
(Questran) 
  
f.  Ezetumibe   







6.5  Anti-hypertensives 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Amlodopine   
b.  Ramipril (Lopace)   
c.  Doxazosin   
d.  Felodipine   
e.  Labetalol   
f.  Atenolol   





6.6  Diuretics 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Bendroflumethiazide   
b.  Furosemide   
c.  Spirinolactone   
d.  Hydrochlorathiazide   






6.7  NSAIDS and Opiods 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Aspirin   
b.  Ibruprofen   
c.  Codeine   
d.  Hydromorphone 
(Dilaudid) 
  
e.  Meperidine   
f.  Oxycodone   








6.8  Other medications 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.   
b.   
c.   
d.   





7. SOUL-D Lab Tests 
 
Date obtained: ___ ___/ ___ ___ (mm/yy)    
 
Lab: 1 KCH      2 GSTT      3 PRU     4 UHL     5 QMS    
6Mayday 7 Other………….. 
 
Test Units Value Ref. range 
Lipids    
a. Triglycerides mmol/L   
b. LDL mmol/L   
c. HDL mmol/L   
d. Total cholesterol mmol/L   
LFTs    
e. ALT (alanine aminotransferase) IU/L   
f. AST (aspartate aminotransferase) IU/L   
g. ALP ( alkaline phosphatase) IU/L  30-130 
h. GGT (gamma-glutamyl transferase) IU/L  1-55 
Renal     
i. Creatinine  umol/L  45-120 
j. eGFR ml/min   
FBC    
k. Total white count (WBC) 10\S\9/l  4.00-11.00 
l. Haemoglobin (Hb) g/dl  11.5-15.5 
m. Platelet count (PLT) 10\S\9/l  150-450 
n. Neutrophils 10\S\9/l  0.20-6.30 
o. Lymphocytes 10\S\9/l  1.30-4.00 
TFTs    
p. Thyroid stimulating hormone (TSH) mU/L  0.30-5.50) 
q. Free thyroxine pmol/L  9.0-25.0 
r. HbA1c %   
s. Prolactin mU/L  < 510mU 
t. C-reactive Protein mg/l  < 5.0 
u. Cortisol nmol/L  130-580 
v. Insulin levels mU/L  4.4-26.0 
u. Plasma glucose (fasting) mmol/L  3.0-6.0 
w. HOMA-IR (v x u)/22.5    







































SOUL-D ID No.:  
 
 
Researcher ID:  
 
 








0.1 Year 1 Visit Checklist 
a. Consent reviewed with participant: 
1Yes  2Withdrawn    3Non-contactable  4 Dead 
b. Questionnaire completed    1 Yes 2 No 
c. Year 1 bloods completed    1 Yes 2 No 
d. Year 1 CRF completed     1 Yes 2 No 
 
0.2 Withdrawals, non-contactables, deaths: 
 
a. Withdrawn  Date __ __/__ __/__ __ 
NB: please complete sections of the CRF using GP records and ensure data 
manager aware so that no further study letters sent out 
 
b. Non-contactable   
Date last seen at GP practice __ __/__ __/__ __ 
NB: please check dates of last prescription uptake as well as general records 
and complete sections of the CRF using GP records 
  
c. If dead 
Date __ __/__ __/__ __  Cause ……………………………….. 
 
d. Main cause of death: 
Non-specific CVD    1 
MI      2  
CVA      3    
Infection     4  
Cancer     5  
Renal failure     6 
Complications from liver disease  7 






1. Socio-demographics data 
 
1.1 What is your legal partnership status? 









1.2 Employment status 
 
Are you currently…. 
 
1 In full-time employment 
2 In part-time employment 
3 On sick leave 
4 Unemployed 
5 Medically retired 
6 A housewife/husband 
7 Retired 
 
The following questions refer to your current main job, or (if you are not 
working now) to your last main job.  Please tick one box only per question. 
 
1.3 Employee or self-employed 
Do (did) you work as an employee or are (were) you self-employed? 
1 Employee 
2 Self-employed with employees 
3 Self-employed / freelance without employees (go to question 1.6) 
 
1.4 Number of employees 
For employees:  Indicate below how many people work (worked) for your 
employer at the place where you work (worked). 
 
For self-employed:  Indicate below how many people you employ (employed).  
Go to question 1.13 when you have completed this question. 
 
Please tick box. 
 
1 1 to 24 









1.5 Supervisory status 
Do (did) you supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other 






Please tick one box to show which best describes the sort of work you do. 
(If you are not working now, please tick a box to show what you did in your 
last job). 
 
PLEASE TICK ONE BOX ONLY. 
 
 1 Modern professional occupations 
Such as:  teacher, nurse, physiotherapist, social worker, welfare officer, artist, 
musician, police officer (sergeant or above), software designer 
 
2 Clerical and intermediate occupations 
Such as:  secretary, personal assistant, clerical worker, office clerk, call centre 
agent, nursing auxiliary, nursery nurse 
 
3 Senior mangers or administrators 
(usually responsible for planning, organising, and co-ordinating work and for 
finance) 
Such as:  finance manager, chief executive 
 
4 Technical and craft occupations 
Such as: motor mechanic, fitter, inspector, plumber, printer, tool maker, 
electrician, gardener, train driver 
 
5 Semi-routine manual and service occupations 
Such as:  postal worker, machine operative, security guard, caretaker, farm 
worker, catering assistant, receptionist, sales assistant 
 
6 Routine manual and service occupations 
Such as:  HGV driver, van driver, cleaner, porter, packer, sewing machinist, 
messenger, labourer, waiter / waitress, bar staff 
 
7 Middle or junior managers 
Such as:  office manager, retail manager, bank manager, restaurant manager, 
warehouse manager, publican 
 
8 Traditional professional occupations 
Such as:  accountant, solicitor, medical practitioner, scientist, civil / 
mechanical engineer 
 
1.7 What is your current (or last) job title? 




















2.1   Microalbuminuria (ACR):  
  
 a. Sample collection: 
1 Data not available (continue to 2.6.2) 
2 Early morning urine 
3 Random sample 
4 Not indicated 
 
 b. Results: 
1 Negative (ACR < 3) 
2 Positive (ACR ≥ 3) 
       
2.2   Proteinuria (urine dipstick) 
  
 a. Sample Collection: 
1 Data not available (continue to 2.6.3) 
2 Early morning urine 
3 Random sample 
4 Not indicated 
 
 b. Results: 
1 Negative (0 – trace on urine dipstick) 
2 Positive (1+ - 3+ on urine dipstick) 




2.3   Attended DECS 
1 Yes  
2 No 
3 Appointment booked (date: ___ ___ /___ ___ / ___ ___ (dd/mm/yy)) 
4 No appointment booked 
 
2.4  DECS coding 
1 No retinopathy 
2 Treated retinopathy 
(laser, photocoagulation, vitrectomy, quiescent retinopathy) 
3 Non-sight threatening retinopathy 
(background, mild/minimal pre-proliferative, mild/moderate non-proliferative) 
4 Sight-threatening retinopathy 
(maculopathy, moderate/severe pre-proliferative, pre-proliferative and 
maculopathy, non-proliferative maculopathy, at risk of and with clinically 
significant macula oedema) 
 





2.6  Laser treatment 
1 Yes  
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
2 No 
 
2.7   Cataracts 
1 Yes  
2 No 
      
2.8  Registered partially sighted, secondary to diabetes 
1 Yes 
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
2 No 
       
Feet: 
 
Foot ulcer since baseline visit 










Macrovascular disease since baseline visit 












2.15  Carotid revascularisation 
1 Yes        
If yes, date:  ___  ___ / ___ ___ (mm/yy) 
2 No 
 
2.16  Limb revascularisation  
1 Yes        






2.17  Amputation 
1 Yes        
If yes, date:  ___ ___ / ___ ___ (mm/yy) 
 If yes: 2 Major 
  1 Minor 
2 No 
 
2.18  Erectile dysfunction (see recruiter booklet for explanation) 





2.19  Severe hypoglycaemia (needing 3rd party assistance, see recruiter 





2.20 If yes how many episodes in last 12 months?  
 
 
Family history of Type 2 or gestational diabetes: 
2.21 1st degree relatives (do not record step family only blood relations) 
 
 Yes1 No2 
 
Not known3 Number 
(c, d, e only) 
a. Mother 
 
    
b. Father 
 
    
c. Brother (n) 
 
    
d. Sister (n) 
 
    
e. Child (n) 
 
















2.22 1st degree relatives with diabetes 
 
 Diabetes? If yes 










a. Mother    
 
    
b. Father    
 
    
c. Brother 
(n) 
   
 
    
d. Sister (n)    
 
    
e. Child (n)    
 
    
 
2.23 1st degree relatives who are obese 
 
Obese? (BMI 30+) 
 Yes No Not known 
a. Mother 
 
   
b. Father 
 
   
c. Brother (n) 
 
   
d. Sister (n) 
 
   
e. Child (n) 
 






3. Current depression 
 
Depression (CIS-R) 
Interviewer: please tick box 






3.2 During the past month, have you been able to enjoy or take an interest in 
things as much as you usually do? 
1 Yes    
2 No 
 
3.3 Any management for depression since baseline? 
1 Self-help (e.g. book/leaflet)        
2 Anti-depressant 
3 Counselling      
4 CBT 
5 Diabetes specific psychological treatment (e.g. MET/MI for diabetes) 
6 No treatment 
7 Not applicable (not depressed) 
 








7 No family history 





4. Current physical/psychological status (QOF screen=grey boxes) 
Date of assessment  
 
Physical examination: 
 Units Value 
a. Height  cm  
b. Seated height  cm  
c. Leg length  difference a-b  
d. Weight  kg  
e. BMI  wt/ht2  
f. Waist circumference  cm  
g. Blood pressure systolic  mmHg  
h. Blood pressure diastolic  mmHg  
 
Neuropathy assessment: 
 Units Value 
Vibration Perception Threshold   
4.1   R 1st toe    volts  
4.2   L 1st toe    volts  
10g monofilament sensation   
Test 5 sites: 1st, 2nd, 3rd, & 5th plantar metatarsal heads and plantar 
aspect of great toe.  If feels < 3/5, abnormal result. 
4.1  R foot      no. of sites /5 
4.2  L foot      no. of sites /5 
  
Foot pulses: 
4.3  R foot dorsalis pedis 1  Present  
2  Absent  
4.4  R foot posterior tibial 1  Present  
2  Absent  
4.5  L foot dorsalis pedis 1  Present 
2  Absent  
4.6  L foot posterior tibial 1  Present  
2  Absent  
 
Depression screening: 
Low mood – use answer from 3.1 1  Yes 
2  No 
  
Loss of interest in activities – use answer from 3.2 1  Yes 
2  No 
  
4.9 Positive screen (if yes to either of the above) 1  Yes 
2  No 
  
4.10 PHQ-9 score from participant questionnaire  
 




          
5. Current cognitive status 
 
Telephone Interview for Cognitive Status (TICS-M) 
Orientation 



























5.5 What is your telephone number (including code)? 








5.6 I’m going to read you a list of 10 words. Please listen carefully and try to      
remember them.  When I am done, tell me as many as you can in any order.  
Ready?  
 
(Read words from list below). 
 
Now, tell me all the words you can remember. 
Yes No 
1 2 Cabin 
1 2 Pipe 
1 2 Elephant 
1 2 Chest 
1 2 Silk 
1 2 Theatre 
1 2 Watch 
1 2 Whip 
1 2 Pillow 
1 2 Giant 
 
Attention/Calculation 































Comprehension, semantic & recent memory 










5.11 Who is the reigning monarch? 




5.12 Who is the Prime Minister now? 










5.14 Please say this, ‘Methodist Episcopal’. 




5.15  Please repeat the list of 10 words I read earlier. 
Yes No 
1 2 Cabin 
1 2 Pipe 
1 2 Elephant 
1 2 Chest 
1 2 Silk 
1 2 Theatre 
1 2 Watch 
1 2 Whip 
1 2 Pillow 





           
NART 
Interviewer:    
I want you to read slowly down this list of words starting here.  (Hand patient 
NART word list and indicate CHORD).  After each word please wait until I say 
‘next’ before reading the next word.  I must warn you that there are many 
words that you probably won’t recognise; in fact most people don’t know 
them, so just have a guess at these, O.K.?  Go ahead: 
 
Column 1 





























































































































































































































6. Medication Review / Current Treatment 
 
6.1  Herbal Remedies 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.   
b.   
c.   
d.   
e.   
f.   
 
6.2  Diabetes tablets 
1  Yes 
2  No 
 
Name Total daily dose Units  
a.  Metformin 
(Glucophage) 
  
b.  Acarbose   
c.  Repaglinide 
(Prandin) 
  
d.  Nateglinide (Starlix)   
e.  Glibenclamide 
(Daomil, Euglucon) 
  
f.  Gliclazide (Diamicron)   
g.  Glimepiride (Amaryl)   
h.  Glipizide (Glibenese, 
Minodiab) 
  







6.3  Insulin 
1  Yes 
2  No 
 
Name Dose (Units) Frequency 
a.  Insulin Lispro 
(Humalog) 
   Once daily                     Twice daily                
  Three times daily            Other: 
b.  Insulin Aspart 
(NovoRapid) 
   Once daily                     Twice daily                
  Three times daily            Other: 
c.  Insulin Glulisine 
(Apidra) 
   Once daily                     Twice daily                
  Three times daily            Other: 
d.  Insulin Glargine 
(Lantus) 
   Once daily                     Twice daily                
  Three times daily            Other: 
e.  Isophane Insulin 
(NPH) 
(eg. Insulatard, Humulin 
I) 
   Once daily                     Twice daily                
  Three times daily            Other: 
f.  Soluble Insulin 
(eg.  Humulin S, 
Actrapid) 
   Once daily                     Twice daily                
  Three times daily            Other: 
g.  Insulin Detemir 
(Levemir) 
   Once daily                     Twice daily                
  Three times daily            Other: 
h.  Humalog Mix 25    Once daily                     Twice daily                
  Three times daily            Other: 
i.  Humalog Mix 50    Once daily                     Twice daily                
  Three times daily            Other: 
j.  NovoMix 30 
(eg.  Mixtard 30) 
   Once daily                     Twice daily                
  Three times daily            Other: 
k.  Other 
Name: 
   Once daily                     Twice daily                
  Three times daily            Other: 
 
 
6.4  Cholesterol – lowering medications 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Atvorvastatin (Lipitor)   
b.  Simvastatin (Zocor)   
c.  Bezafibrate (Bezalip)   
d.  Fenofibrate (Lipantil)   
e.  Colestyramine 
(Questran) 
  
f.  Ezetumibe   







6.5  Anti-hypertensives 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Amlodopine   
b.  Ramipril (Lopace)   
c.  Doxazosin   
d.  Felodipine   
e.  Labetalol   
f.  Atenolol   





6.6  Diuretics 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Bendroflumethiazide   
b.  Furosemide   
c.  Spirinolactone   
d.  Hydrochlorathiazide   






6.7  NSAIDS and Opiods 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.  Aspirin   
b.  Ibruprofen   
c.  Codeine   
d.  Hydromorphone 
(Dilaudid) 
  
e.  Meperidine   
f.  Oxycodone   








6.8  Other medications 
1  Yes 
2  No 
 
Name Total daily dose Units 
a.   
b.   
c.   
d.   
e.   
f.   
g.   
h.   
i.   
j.   





7. SOUL-D Lab Tests 
 
Date obtained: ___ ___/ ___ ___ (mm/yy)    
 
Lab: 1 KCH      2 GSTT      3 PRU     4 UHL     5 QMS    
6Mayday 7 Other………….. 
 
Test Units Value Ref. range 
Lipids    
a. Triglycerides mmol/L  0.5-2.0 
b. LDL mmol/L  1.0-3.0 
c. HDL mmol/L  >1.0 
d. Total cholesterol mmol/L  1.0-5.0 
LFTs    
e. ALT (alanine aminotransferase) IU/L  5-55 
f. AST (aspartate aminotransferase) IU/L  10-50 
g. ALP ( alkaline phosphatase) IU/L  30-130 
h. GGT (gamma-glutamyl transferase) IU/L  1-55 
Renal     
i. Creatinine  umol/L  45-120 
j. eGFR ml/min   
FBC    
k. Total white count (WBC) 10\S\9/l  4.00-11.00 
l. Haemoglobin (Hb) g/dl  11.5-15.5 
m. Platelet count (PLT) 10\S\9/l  150-450 
n. Neutrophils 10\S\9/l  0.20-6.30 
o. Lymphocytes 10\S\9/l  1.30-4.00 
TFTs    
p. Thyroid stimulating hormone (TSH) mU/L  0.30-5.50 
q. Free thyroxine pmol/L  9.0-25.0 
r. HbA1c %  <7.5% 
s. Prolactin mU/L  < 410 
t. C-reactive Protein mg/l  < 5.0 
u. Cortisol nmol/L  130-580 
v. Insulin levels mU/L  4.4-26.0 
w. Plasma glucose (fasting) mmol/L  3.0-6.0 
x. HOMA-IR (v x u)/22.5    





1 Over the last two weeks, how often/how much have you been bothered by any of the following problems?
Not  Several More than Nearly
at all days half the days every day
a) Little interest or pleasure in doing things !0 !1 !2 !3
b) Feeling down, depressed, or hopeless !0 !1 !2 !3
c) Trouble falling or staying asleep, or sleeping too much !0 !1 !2 !3
d) Feeling tired or having little energy !0 !1 !2 !3
e) Poor appetite or overeating !0 !1 !2 !3
f) Feeling bad about yourself  or that you are a failure !0 !1 !2 !3
or have let yourself or your family down
g) Trouble concentrating on things, such as reading the !0 !1 !2 !3
newspaper or watching television
h) Moving or speaking so slowly that other people could !0 !1 !2 !3
have noticed or being so fidgety or restless that you 
have been moving around a lot more than usual
i) Thoughts that you would be better off dead or of !0 !1 !2 !3





55 In the last 12 months, have you ever lived with someone as a couple and that relationship ended in
separation or divorce?
No  !1 Yes  !2
56 In the last 12 months, has a spouse/partner, child, or other loved one died?
No  !1 Yes  !2
57 In the last 12 months, have you ever seen something violent happen to someone (e.g., attacked or beaten)
or seen someone killed?
No  !1 Yes  !2
58 In the last 12 months, have you ever been in the immediate area or place where a major natural disaster
occurred such as a major fire, flood, tornado, earthquake, or other natural disaster? 
No  !1 Yes  !2
59 In the last 12 months, have you ever had a serious accident?
No  !1 Yes  !2
60 In the last 12 months, has one of you children ever had a near-fatal accident or life-threatening illness? 
No  !1 Yes  !2
61 In the last 12 months, has one of you children ever had a serious illness or disability?
No  !1 Yes  !2
62 In the last 12 months, have you ever been in combat in a war, lived near a war zone, or been present during
a political uprising?
No  !1 Yes  !2
63 In the last 12 months, have you ever experienced a period where you slept in a park, abandoned building,
the street, a train or bus, in a shelter for homeless people or in another temporary residence or with a
friend or relative because you had no money to pay for rent?
No  !1 Yes  !2
64 In the last 12 months, have you ever been attacked, mugged, robbed, or been the victim of a serious crime? 
No  !1 Yes  !2
15
65 In the last 12 months, has anyone ever injured you with a weapon – gun, knife, stick, etc.?
No  !1 Yes  !2
66 In the last 12 months, has anyone ever hit you, bit you, slapped you, kicked you, or forced you to have sex  
against your wishes?
No  !1 Yes  !2
